4 results match your criteria: "IRCCS Humanitas University Research Hospital[Affiliation]"
The impact of survivorship bias in glioblastoma research.
Crit Rev Oncol Hematol
August 2023
Department of Oncology, University of Oxford, Oxford, UK; Department of Computing Sciences, Bocconi University, Milan, Italy; Institute for Data Science and Analytics, Bocconi University, Milano, Italy.
Despite advances in the therapy of Central Nervous System (CNS) malignancies, treatment of glioblastoma (GB) poses significant challenges due to GB resistance and high recurrence rates following post-operative radio-chemotherapy. The majority of prognostic and predictive GB biomarkers are currently developed using tumour samples obtained through surgical interventions. However, the selection criteria adopted by different neurosurgeons to determine which cases are suitable for surgery make operated patients not representative of all GB cases.
View Article and Find Full Text PDFNonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination.
Br J Cancer
October 2023
Anatomic Pathology Unit, IRCCS Humanitas University Research Hospital, Milan, Italy.
Recently, Liau et al. reported the results of Phase 3 clinical trial testing DCVax-L vaccines on patients with glioblastoma. Despite the promising and significant results obtained, the study design and the long-lasting period of recruitment of this work deserve some reflection.
View Article and Find Full Text PDFThe Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective.
Front Med (Lausanne)
June 2022
Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland.
Article Synopsis
- Hepatocellular carcinoma (HCC) often arises from cirrhosis linked to chronic liver disease (CLD) and inflammation, which sets the stage for tumor development.
- Next generation sequencing has revealed various molecular changes in HCC, but more research is needed on the inflamed liver environment that leads to cancer and affects recurrence.
- Ongoing studies aim to analyze the genetic and protein changes in CLD, helping to uncover biomarkers for early detection and potential new treatments for both primary and recurrent HCC.
Adjuvant Radiotherapy in Patients With Pancreatic Adenocarcinoma. Is It Still Appealing in Clinical Trials? A Meta-analysis and Review of the Literature.
Anticancer Res
October 2021
Unit of Radiation Oncology, Pisa University Hospital, Pisa, Italy.
Aim: Pancreatic adenocarcinoma is a life-threatening disease with a rising frequency and the fourth leading cause of cancer death. This review aimed to assess the impact of postoperative radiotherapy through a meta-analysis of prospective randomized studies.
Materials And Methods: Six studies met the inclusion criteria and were analyzed to calculate the cumulative risk of death (hazard ratio) in patients affected by pancreatic cancer treated with or without radiotherapy.